FDA Drug Recalls
17,898 recalls, newest first
Class II · Moderate risk Terminated May 13, 2024
Reason CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.
Class II · Moderate risk Ongoing May 13, 2024
Reason CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.
Class II · Moderate risk Ongoing May 13, 2024
Reason CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.
Class II · Moderate risk Terminated May 13, 2024
Reason Subpotent product in addition to having out-of-specification results for impurities.
Class III · Low risk Ongoing May 10, 2024
Reason Labeling: Not Elsewhere Classified: Back Label states 'Each contains: cephalexin monohydrate, USP equivalent to 5g' instead of Each Bottle…
Class III · Low risk Ongoing May 10, 2024
Reason Labeling: Not Elsewhere Classified: Back Label states Each contains: cephalexin monohydrate, USP equivalent to 5g' on the back label instead of…
Class III · Low risk Ongoing May 10, 2024
Reason Labeling: Not Elsewhere Classified: Back Label states 'Each contains: cephalexin monohydrate, USP equivalent to 5g' instead of Each Bottle…
Class III · Low risk Ongoing May 10, 2024
Reason Labeling: Not Elsewhere Classified: Back label states Each contains: cephalexin monohydrate, USP equivalent to 2.5g' instead of Each Bottle…
Class III · Low risk Ongoing May 10, 2024
Reason Labeling: Not Elsewhere Classified: Front label states 100 Tablets instead of 100 ml and on the back label 'Each Tablet contains' instead of…
Class II · Moderate risk Ongoing May 10, 2024
Reason CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.
Class II · Moderate risk Ongoing May 10, 2024
Reason CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.
Class II · Moderate risk Ongoing May 10, 2024
Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Class II · Moderate risk Terminated May 8, 2024
Reason Defective container: lack of seal integrity.
Class II · Moderate risk Ongoing May 7, 2024
Reason Failed Stability Specifications - at 12 months 2-8 degrees C followed by 6 weeks at 25 degrees C.
Class II · Moderate risk Ongoing May 7, 2024
Reason Presence of foreign substance: plastic-like substance.
Class II · Moderate risk Ongoing May 6, 2024
Reason Presence of Foreign Substance: metal in tablet
Class II · Moderate risk Terminated May 2, 2024
Reason Presence of Foreign Tablets: Manufacturer received a report from a Pharmacist who reported finding a tablet of baclofen in a bottle of 1000-count…
Class III · Low risk Ongoing May 1, 2024
Reason Failed Impurities/Degradation Specifications
Class II · Moderate risk Ongoing May 1, 2024
Reason Microbial Contamination of Non-Sterile Products - Presence of Acetobacter nitrogenifigens bacteria
Class II · Moderate risk Ongoing May 1, 2024
Reason Microbial Contamination of Non-Sterile Products - Presence of Acetobacter nitrogenifigens bacteria
Class II · Moderate risk Completed Apr 30, 2024
Reason Failed Impurities/Degradation Specifications
Class II · Moderate risk Completed Apr 30, 2024
Reason Failed Impurities/Degradation Specifications
Class III · Low risk Completed Apr 30, 2024
Reason Labeling: Wrong Barcode
Class I · High risk Completed Apr 29, 2024
Reason Labeling: Label mix-up - ephedrine syringes mislabeled as phenylephrine.
Class II · Moderate risk Ongoing Apr 29, 2024
Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit